1.
Cleve Clin J Med
; 91(7): 415-423, 2024 Jul 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38950981
RESUMEN
Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.